Kateri A. Ahrendt - Concepedia

Author

Kateri A. Ahrendt

Array BioPharma (United States)ORCID

Also Known As

Ahrendt, K.A., Ahrendt, Kateri A., K. A. Ahrendt, Kateri A. Ahrendt, Kateri Ahrendt

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Array BioPharma (United States)University of California, Berkeley Colorado State University Lawrence Berkeley National Laboratory

About

Kateri A. Ahrendt is an author at Array BioPharma (United States) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	210
2	Natural Sciences	3	3	83
3	Biochemistry	3	3	92
4	Engineering	2	2	1.7K
5	Biomolecular Engineering	1	1	1.6K

Kateri A. Ahrendt

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
New Strategies for Organic Catalysis: The First Highly Enantioselective Organocatalytic Diels−Alder Reaction Kateri A. Ahrendt, Christopher J. Borths, David W. C. MacMillan Journal of the American Chemical Society Chemical EngineeringOrganic CatalysisEngineeringNovel OrganocatalystsAltmetric Attention Score	2000	1.6K
Synthesis of a Tricyclic Mescaline Analogue by Catalytic C−H Bond Activation Kateri A. Ahrendt, Robert G. Bergman, Jonathan A. Ellman Organic Letters	2003	98
Annulation of Aromatic Imines via Directed C−H Bond Activation Reema K. Thalji, Kateri A. Ahrendt, Robert G. Bergman, The Journal of Organic Chemistry	2005	93
A Concise Asymmetric Synthesis of the ADE Fragment of Nakadomarin A Kateri A. Ahrendt, Robert M. Williams Organic Letters	2004	79
Pyrazolopyridine Inhibitors of B-Raf<sup>V600E</sup>. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors Steve Wenglowsky, Li Ren, Kateri A. Ahrendt, ACS Medicinal Chemistry Letters	2011	66
Pyrazolopyridine inhibitors of B-RafV600E. Part 2: Structure–activity relationships Steve Wenglowsky, Kateri A. Ahrendt, Alex J. Buckmelter, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryMedicineRational Drug DesignPharmacology	2011	55
A Noncompetitive Inhibitor for<i>Mycobacterium tuberculosis</i>’s Class IIa Fructose 1,6-Bisphosphate Aldolase Glenn C. Capodagli, Wafik G. Sedhom, Mary Jackson, Biochemistry Class IiBiosynthesisAntimicrobial Drug DiscoveryAldo-keto ReductaseBiochemistry	2013	54
Pyrazolopyridine inhibitors of B-RafV600E. Part 3: An increase in aqueous solubility via the disruption of crystal packing Steve Wenglowsky, David Moreno‐Mateos, Joachim Rudolph, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryPharmaceutical ScienceAqueous SolubilityNatural SciencesMedicine	2011	45
Abstract #1795: In Vitro and in vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB2. Tracy Pheneger, Karyn Bouhana, Deborah Anderson, Cancer Research Small Molecule InhibitorPharmacotherapyTumor BiologyTranslational PharmacologyMolecular Pharmacology	2009	21
Identification of potent and broad-Spectrum antibiotics from SAR studies of a synthetic vancomycin analogue Kateri A. Ahrendt, Jacob Olsen, Masahiro Wakao, Bioorganic & Medicinal Chemistry Letters Sar StudiesAntibioticsMedicineAntibacterial AgentAntimicrobial Chemotherapy	2003	18

Page 1